Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4185-4190

  Balasubramanian, V ^a   Solapure, Suresh ^a   Shandil, Radha ^a   Gaonkar, Sheshagiri ^a   Mahesh, K N ^a   Reddy, Jitender ^a   Deshpande, Abhijeet ^a   Bharath, Sowmya ^a   Kumar, Naveen ^a   Wright, Lindsay ^a   Melnick, David ^a   Butler, Scott L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5847; AZD 5847DISODIUM PHOSPHATE; AZD5847; AZD5847 DISODIUM PHOSPHATE; DRUG METABOLITE; OXAZOLIDINONE DERIVATIVE; PRODRUG; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; POSIZOLID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CFU COUNTING; CHRONOTHERAPY; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; EVALUATION STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DOSE CALCULATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS, PULMONARY;

ANIMALS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS, PULMONARY;

EID: 84903196128     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00137-14     Document Type: Article

References (22)

1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. http://dx.doi.org/10.1016/S0140-6736(06) 69573-1. (Pubitemid 44780738)
2. World Health Organization. 2013. Global tuberculosis report 2013. Report WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland.
3. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-192. http://dx.doi.org/10.1378/chest. 07-1988. (Pubitemid 352008783)
4. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. 2008. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178:1180-1185. http://dx.doi.org/10.1164/rccm. 200806-892OC.
5. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388-391. http://dx.doi.org/10.1093/jac/dkp171.
6. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
7. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42:1111-1117. http://dx.doi.org/10.1086/501356.
8. Forrest A, Drusano GL. 2007. Modeling of toxicities due to antibiotics, p 449-462. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd edition (infectious disease and therapy). Informa Healthcare USA, Inc., New York, NY.
9. Anonymous. 2010. Zyvox. U.S. Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021130s022lbl.pdf.
10. Gravestock MB, Acton DG, Betts MJ, Dennis M, Hatter G, McGregor A, Swain ML, Wilson RG, Woods L, Wookey A. 2003. New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains. Bioorg. Med. Chem. Lett. 13:4179-4186. (Pubitemid 37410308)
11. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK. 2014. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 58:495-502. http://dx.doi.org/10.1128/AAC.01903- 13.
12. Solapure S, Dinesh N, Shandil R, Ramachandran V, Sharma S, Bhattacharjee D, Ganguly S, Reddy J, Ahuja V, Panduga V, Parab M, Vishwas KG, Kumar N, Balganesh M, Balasubramanian V. 2013. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57: 2506-2510. http://dx.doi.org/ 10.1128/AAC.00023-13.
13. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582. http://dx.doi.org/10.1128/AAC.00414- 06. (Pubitemid 46185275)
14. P SH, Solapure Mukherjee S, Nandi K, Waterson V, Shandil D, Balganesh R, Sambandamurthy M, Raichurkar VK, Deshpande AK, Ghosh A, Awasthy A, Shanbhag D, Sheikh G, McMiken G, Puttur H, Reddy J, Werngren J, Read J, Kumar MRM, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V. 2014. Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 58:61-70. http://dx.doi.org/10.1128/AAC.01751-13.
15. Fernley HN. 1971. Mammalian alkaline phosphatases, p 417-447. In Boyer PD (ed), The enzymes, 3rd ed. Academic Press, New York, NY.
16. Hollander VP. 1971. Acid phosphatases, p 449-498. In Boyer PD (ed), The enzymes, 3rd ed. Academic Press, New York, NY.
17. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. 2011. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:239-245. http://dx.doi.org/10.1128/AAC.00849-10.
18. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
19. Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Moller N. 2010. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. J. Antimicrob. Chemother. 65:962-973. http://dx.doi.org/10.1093/jac/dkq052.
20. Louie A, Brown D, Files K, Swift M, Fikes S, Drusano G. 2012. Pharmacodynamics of PNU-100480 (U, Sutezolid), a new oxazolidinone, in combination with its active metabolite in the killing of Mycobacterium tuberculosis (Mtb) in an in vitro hollow fiber infection model (HFIM), abstr A-1265. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
21. Reele S, Xiao AJ, Das S, Balasubramanian V, Melnick D. Flexible single day ascending dose (SDAD) studies with AZD5847 demonstrate oral dosing regimens with potential utility for the treatment of tuberculosis (TB), abstr A1-1734. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. Reele S, Xiao AJ, Das S, Balasubramanian V, Melnick D. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB), abstr A1-1735. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.